The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore, SARS-CoV-2 was passaged in vitro in the pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Jochmans, Dirk, Liu, Cheng, Donckers, Kim, Stoycheva, Antitsa, Boland, Sandro, Stevens, Sarah K., De Vita, Chloe, Vanmechelen, Bert, Maes, Piet, Trüeb, Bettina, Ebert, Nadine, Thiel, Volker, De Jonghe, Steven, Vangeel, Laura, Bardiot, Dorothée, Jekle, Andreas, Blatt, Lawrence M., Beigelman, Leonid, Symons, Julian A., Raboisson, Pierre, Chaltin, Patrick, Marchand, Arnaud, Neyts, Johan, Deval, Jerome, Vandyck, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973015/
https://www.ncbi.nlm.nih.gov/pubmed/36625640
http://dx.doi.org/10.1128/mbio.02815-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973015/
https://www.ncbi.nlm.nih.gov/pubmed/36625640
http://dx.doi.org/10.1128/mbio.02815-22

Ejemplares similares